{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T23:10:03Z","timestamp":1759014603769,"version":"3.44.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pharmthera.2023.108509","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T21:28:53Z","timestamp":1691702933000},"page":"108509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antithrombotic therapy following transcatheter aortic valve intervention"],"prefix":"10.1016","volume":"250","author":[{"given":"Harish","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazia","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Leick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar N.","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Adnan","family":"Nadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.pharmthera.2023.108509_bb0005","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.jcin.2016.06.025","article-title":"Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing Transcatheter aortic valve replacement","volume":"9","author":"Abdul-Jawad Altisent","year":"2016","journal-title":"JACC. Cardiovascular Interventions"},{"key":"10.1016\/j.pharmthera.2023.108509_bb0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.carrev.2021.01.016","article-title":"Single versus dual antiplatelet therapy after Transcatheter aortic valve replacement: A Meta-analysis of randomized clinical trials","volume":"34","author":"Ahmad","year":"2022","journal-title":"Cardiovascular Revascularization Medicine"},{"key":"10.1016\/j.pharmthera.2023.108509_bb0015","first-page":"5","article-title":"Cerebrovascular events after transcatheter aortic valve implantation","author":"Armijo","year":"2018","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108509_bb0020","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jcin.2023.02.039","article-title":"Sex differences in outcomes after Transcatheter aortic valve replacement: A POPular TAVI subanalysis","volume":"16","author":"van Bergeijk","year":"2023","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"19","key":"10.1016\/j.pharmthera.2023.108509_bb0025","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.jacc.2020.03.022","article-title":"Bioprosthetic aortic valve leaflet thickening in the Evolut low risk sub-study","volume":"75","author":"Blanke","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"24","key":"10.1016\/j.pharmthera.2023.108509_bb0030","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.jcin.2021.09.019","article-title":"Subclinical leaflet thrombosis after Transcatheter aortic valve replacement: A Meta-analysis","volume":"14","author":"Bogyi","year":"2021","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"15","key":"10.1016\/j.pharmthera.2023.108509_bb0035","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without Clopidogrel after Transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108509_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019604","article-title":"Aspirin alone versus dual antiplatelet therapy after transcatheter aortic valve implantation: A systematic review and patient-level meta-analysis","volume":"10","author":"Brouwer","year":"2021","journal-title":"Journal of the American Heart Association"},{"issue":"21","key":"10.1016\/j.pharmthera.2023.108509_bb0045","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.jacc.2020.09.595","article-title":"STS-ACC TVT registry of Transcatheter aortic valve replacement","volume":"76","author":"Carroll","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"29","key":"10.1016\/j.pharmthera.2023.108509_bb0050","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: The ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108509_bb0055","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after Transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108509_bb0060","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1911426","article-title":"Reduced leaflet motion after Transcatheter aortic-valve replacement","volume":"382","author":"De Backer","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.pharmthera.2023.108509_bb0065","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jcin.2021.05.025","article-title":"TAVR patients requiring anticoagulation: Direct Oral anticoagulant or vitamin K antagonist?","volume":"14","author":"Didier","year":"2021","journal-title":"JACC. Cardiovascular Interventions"},{"key":"10.1016\/j.pharmthera.2023.108509_bb0070","first-page":"28","article-title":"Efficacy and safety of NOACs compared with VKAs for patients with atrial fibrillation after Transcatheter aortic valve implantation: A system review and Meta-analysis","author":"Ge","year":"2022","journal-title":"Clinical and Applied Thrombosis"},{"issue":"24","key":"10.1016\/j.pharmthera.2023.108509_bb0075","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.jacc.2014.08.052","article-title":"Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement","volume":"64","author":"G\u00e9n\u00e9reux","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"19","key":"10.1016\/j.pharmthera.2023.108509_bb0080","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/eurheartj\/ehaa799","article-title":"Valve academic research consortium 3: Updated endpoint definitions for aortic valve clinical research","volume":"42","author":"G\u00e9n\u00e9reux","year":"2021","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108509_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168852","article-title":"Subacute subclinical brain infarctions after transcatheter aortic valve implantation negatively impact cognitive function in long-term follow-up","volume":"12","author":"Ghanem","year":"2017","journal-title":"PLoS One"},{"issue":"5\u20136","key":"10.1016\/j.pharmthera.2023.108509_bb0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/24748706.2017.1366086","article-title":"Clinical or symptomatic leaflet thrombosis following Transcatheter aortic valve replacement: Insights from the U.S. FDA MAUDE database","volume":"1","author":"Hafiz","year":"2017","journal-title":"Structural Heart"},{"issue":"23","key":"10.1016\/j.pharmthera.2023.108509_bb0095","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2019.7525","article-title":"Association between Transcatheter aortic valve replacement and early Postprocedural stroke","volume":"321","author":"Huded","year":"2019","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108509_bb0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.amjcard.2011.08.038","article-title":"Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position","volume":"109","author":"Jander","year":"2012","journal-title":"The American Journal of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108509_bb0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcin.2018.10.005","article-title":"Assessment of platelet REACtivity after Transcatheter aortic valve replacement: The REAC-TAVI trial","volume":"12","author":"Jimenez Diaz","year":"2019","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"16","key":"10.1016\/j.pharmthera.2023.108509_bb0110","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after Transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108509_bb0115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jcin.2017.01.045","article-title":"Clinical bioprosthetic heart valve thrombosis after Transcatheter aortic valve replacement: Incidence, characteristics, and treatment outcomes","volume":"10","author":"Jose","year":"2017","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"14","key":"10.1016\/j.pharmthera.2023.108509_bb0120","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa2204961","article-title":"Cerebral embolic protection during Transcatheter aortic-valve replacement","volume":"387","author":"Kapadia","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"17","key":"10.1016\/j.pharmthera.2023.108509_bb0125","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.114.009834","article-title":"Long-term outcomes of inoperable patients with aortic stenosis randomly assigned to transcatheter aortic valve replacement or standard therapy","volume":"130","author":"Kapadia","year":"2014","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108509_bb0130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4244\/EIJY14M05_09","article-title":"The effect of coronary artery disease defined by quantitative coronary angiography and SYNTAX score upon outcome after transcatheter aortic valve implantation (TAVI) using the Edwards bioprosthesis","volume":"11","author":"Khawaja","year":"2015","journal-title":"EuroIntervention."},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108509_bb0135","doi-asserted-by":"crossref","first-page":"E010097","DOI":"10.1161\/CIRCINTERVENTIONS.120.010097","article-title":"Aspirin versus Clopidogrel as single antithrombotic therapy after Transcatheter aortic valve replacement: Insight from the OCEAN-TAVI registry","volume":"14","author":"Kobari","year":"2021","journal-title":"Circulation. Cardiovascular Interventions"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108509_bb0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcin.2022.10.010","article-title":"No antithrombotic therapy after Transcatheter aortic valve replacement: Insight from the OCEAN-TAVI registry","volume":"16","author":"Kobari","year":"2023","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108509_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005960","article-title":"Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy: A systematic review and Meta-analysis","volume":"6","author":"Kotronias","year":"2017","journal-title":"Journal of the American Heart Association"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108509_bb0150","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.amjcard.2019.08.024","article-title":"Meta-analysis comparing outcomes in patients undergoing Transcatheter aortic valve implantation with versus without percutaneous coronary intervention","volume":"124","author":"Lateef","year":"2019","journal-title":"The American Journal of Cardiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108509_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001779","article-title":"Treatment and clinical outcomes of transcatheter heart valve thrombosis","volume":"8","author":"Latib","year":"2015","journal-title":"Circulation. Cardiovascular Interventions"},{"issue":"17","key":"10.1016\/j.pharmthera.2023.108509_bb0160","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","article-title":"Transcatheter or surgical aortic-valve replacement in intermediate-risk patients","volume":"374","author":"Leon","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2023.108509_bb0165","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"Mack","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2023.108509_bb0170","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1509233","article-title":"Possible subclinical leaflet thrombosis in bioprosthetic aortic valves","volume":"373","author":"Makkar","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108509_bb0175","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1910555","article-title":"Five-year outcomes of Transcatheter or surgical aortic-valve replacement","volume":"382","author":"Makkar","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108509_bb0180","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/ccd.30213","article-title":"Novel oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis","volume":"99","author":"Memon","year":"2022","journal-title":"Catheterization and Cardiovascular Interventions"},{"issue":"18","key":"10.1016\/j.pharmthera.2023.108509_bb0185","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jcin.2022.07.014","article-title":"Apixaban and valve thrombosis after Transcatheter aortic valve replacement: The ATLANTIS-4D-CT randomized clinical trial substudy","volume":"15","author":"Montalescot","year":"2022","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108509_bb0190","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jcin.2019.11.022","article-title":"Late cerebrovascular events following Transcatheter aortic valve replacement","volume":"13","author":"Muntan\u00e9-Carol","year":"2020","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108509_bb0195","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jcin.2021.03.024","article-title":"Development and validation of a practical model to identify patients at risk of bleeding after TAVR","volume":"14","author":"Navarese","year":"2021","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"18","key":"10.1016\/j.pharmthera.2023.108509_bb0200","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without Clopidogrel after Transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"25","key":"10.1016\/j.pharmthera.2023.108509_bb0205","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1161\/CIRCULATIONAHA.112.110981","article-title":"Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation","volume":"126","author":"Nombela-Franco","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.pharmthera.2023.108509_bb0210","series-title":"ACC\/AHA guideline for the Management of Patients with Valvular heart disease: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"2021","author":"Otto","year":"2020"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108509_bb0215","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: The ADAPT-TAVR randomized clinical trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation."},{"issue":"14","key":"10.1016\/j.pharmthera.2023.108509_bb0220","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jcin.2017.04.034","article-title":"Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing Transcatheter aortic valve replacement","volume":"10","author":"Piccolo","year":"2017","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108509_bb0225","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/ejcts\/ezu201","article-title":"Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: Lessons from a case series","volume":"47","author":"Pislaru","year":"2015","journal-title":"European Journal of Cardio-Thoracic Surgery"},{"issue":"18","key":"10.1016\/j.pharmthera.2023.108509_bb0230","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","article-title":"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients","volume":"380","author":"Popma","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"13","key":"10.1016\/j.pharmthera.2023.108509_bb0235","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","volume":"10","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108509_bb0240","doi-asserted-by":"crossref","first-page":"E009983","DOI":"10.1161\/CIRCINTERVENTIONS.120.009983","article-title":"Randomized trial of aspirin versus warfarin after Transcatheter aortic valve replacement in low-risk patients","volume":"14","author":"Rogers","year":"2021","journal-title":"Circulation. Cardiovascular Interventions"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108509_bb0245","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jcin.2022.01.018","article-title":"New-onset atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis","volume":"15","author":"Ryan","year":"2022","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108509_bb0250","doi-asserted-by":"crossref","first-page":"E431","DOI":"10.1002\/ccd.29124","article-title":"Ten year follow-up of high-risk patients treated during the early experience with transcatheter aortic valve replacement","volume":"97","author":"Sathananthan","year":"2021","journal-title":"Catheterization and Cardiovascular Interventions"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108509_bb0255","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijcard.2014.04.170","article-title":"SAT-TAVI (single antiplatelet therapy for TAVI) study: A pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation","volume":"174","author":"Stabile","year":"2014","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108509_bb0260","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023561","article-title":"Use of direct Oral anticoagulant and outcomes in patients with atrial fibrillation after Transcatheter aortic valve replacement: Insights from the STS\/ACC TVT registry","volume":"11","author":"Tanawuttiwat","year":"2022","journal-title":"Journal of the American Heart Association"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108509_bb0265","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jcin.2014.04.018","article-title":"Cerebrovascular events post-transcatheter aortic valve replacement in a large cohort of patients: A FRANCE-2 registry substudy","volume":"7","author":"Tchetche","year":"2014","journal-title":"JACC. Cardiovascular Interventions"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108509_bb0270","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108509_bb0275","first-page":"1","article-title":"ESC\/EACTS guidelines for the management of valvular heart disease","volume":"2021","author":"Vahanian","year":"2021","journal-title":"European Heart Journal"},{"author":"VAJ","key":"10.1016\/j.pharmthera.2023.108509_bb0280"},{"issue":"23","key":"10.1016\/j.pharmthera.2023.108509_bb0285","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"26","key":"10.1016\/j.pharmthera.2023.108509_bb0290","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1056\/NEJMsa1901109","article-title":"Procedural volume and outcomes for Transcatheter aortic-valve replacement","volume":"380","author":"Vemulapalli","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108509_bb0295","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.carrev.2022.06.011","article-title":"Leaflet thickening and motion after Transcatheter aortic valve replacement: Design and rationale of the Rotterdam edoxaban trial","volume":"44","author":"van Wiechen","year":"2022","journal-title":"Cardiovascular Revascularization Medicine"},{"issue":"23","key":"10.1016\/j.pharmthera.2023.108509_bb0300","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023395","article-title":"Novel neuroimaging evidence of brain lesions following transcatheter aortic valve replacement","volume":"10","author":"Xiong","year":"2021","journal-title":"Journal of the American Heart Association"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:34:44Z","timestamp":1759012484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823001730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":60,"alternative-id":["S0163725823001730"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108509","relation":{},"ISSN":["0163-7258"],"issn-type":[{"type":"print","value":"0163-7258"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic therapy following transcatheter aortic valve intervention","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108509"}}